Image: ModernaTX, Inc., the primary operating subsidiary and official web domain of Moderna, Inc.

A new mRNA influenza vaccine from Moderna, approved by the U.S. Food and Drug Administration (FDA) on August 5, has already been linked to 78 reports of adverse events in a federal safety monitoring system.

MFLUSIVA is reportedly a vaccine for active immunization against influenza caused by virus subtypes A and B contained in the vaccine.

But does the vaccine present a greater threat than the influenza it aims to prevent? Reports filed in the Vaccine Adverse Event Reporting System (VAERS) through late October document instances of sudden mobility…

Read the full article at THEGATEWAYPUNDIT.COM